It could be forgiven, especially these days, for thinking that drug maker Pfizer (NYSE: PFE) was all COVID, all the time. There's a lot more to Pfizer than just COVID-19 vaccines, though. The company recently demonstrated as much with approval of a new drug targeting a disease that has nothing to do with COVID-19. I'm bullish on Pfizer because not only does this company have a share in fighting one of the biggest diseases around, it's not stopping there. Pfizer spent much of the early going of the last year flat. From earliest January to early April, the company hovered around the $33-$35 range.
https://www.tipranks.com/news/article/pfizer-lands-approval-for-new-non-covid-drug?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2022 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 5 2021 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック